Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine

Headache

Volumn 51, Issue 4, 2011, Pages 533-543

  Hewitt, David J ^a   Martin, Vincent ^b   Lipton, Richard B ^c   Brandes, Jan ^d   Ceesay, Paulette ^a   Gottwald, Regina ^a   Schaefer, Eleanor ^a   Lines, Christopher ^a   Ho, Tony W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetaminophen; Calcitonin gene related peptide; Combination; Ibuprofen; Nonsteroidal anti inflammatory drug; Telcagepant

Indexed keywords

ANALGESIC AGENT; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PLACEBO; TELCAGEPANT; TRIPTAN DERIVATIVE;

ACUTE DISEASE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

ACETAMINOPHEN; ADULT; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IBUPROFEN; IMIDAZOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 79953700561     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01860.x     Document Type: Article

References (30)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment.N Engl J Med. 2002;345:257-270. (Pubitemid 34438866)
2. Cutrer FM. Pathophysiology of migraine. Semin Neurol. 2010;30:120-130. Epub 2010 Mar 29.
3. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT-1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001;358:1668-1675. (Pubitemid 33124324)
4. Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalagia. 1995;15(Suppl. 15):14-20.
5. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000;160:3486-3492.
6. Peatfield RC, Petty RG, Rose FC. Double blind comparison of mefenamic acid and acetaminophen (paracetamol) in migraine. Cephalalgia. 1983;3:129-134. (Pubitemid 13044344)
7. Suthisisang C, Poolsup N, Kittikulsuth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: Systematic review and meta-analysis. Ann Pharmacother. 2007;41:1782-1791. (Pubitemid 350044339)
8. Misra UK, Kalita J, Yadav RK. Rizatriptan vs ibuprofen in migraine: A randomized placebo-controlled trial. J Headache Pain. 2007;8:175-179. (Pubitemid 47062589)
9. Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: A randomised placebo-controlled trial. Postgrad Med J. 2004;80:720-723. (Pubitemid 39627104)
10. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: A comparison with acetylsalicylic acid and placebo. Cephalalgia. 1995;15:531-535.
11. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24:947-954. (Pubitemid 39471921)
12. Codispoti JR, Prior MJ, Fu M, Harte CM, Nelso EB. Efficacy of nonprescription doses of ibuprofen for treating migraine headache: A randomized controlled trial. Headache. 2001;41:665-679. (Pubitemid 32777749)
13. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptannaproxen for acute treatment of migraine: A randomized trial. JAMA. 2007;297:1443-1454. (Pubitemid 46556470)
14. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983-991.
15. Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache. 2008;48:921-930. (Pubitemid 351792734)
16. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 2004;4:10.
17. Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: Unravelling the role of CGRP in migraine. Trends Pharmacol Sci. 2007;28:580-587. (Pubitemid 350026615)
18. Edvinsson L. Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists. Expert Opin Ther Targets. 2007;11:1179-1188. (Pubitemid 47527323)
19. Goadsby PJ. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs. 2005;65:2557-2567. (Pubitemid 43049952)
20. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115-2123.
21. Connor KM, Shapiro RE, Diener H-C, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970-977.
22. Ho AP, Dahlof CGH, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30:1443-1457.
23. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl. 1):9-160.
24. Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD. Validation of a new quality of life questionnaire for acute migraine headache. Headache. 1995;35:330-337.
25. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
26. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika. 1976;63:655-660.
27. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
28. Haberer LJ, Walls CM, Lener SE, Taylor DR, McDonald SA. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2010;50:357-373.
29. Diener HC, Schorn CF, Bingel U, Dodick DW. The importance of placebo in headache research. Cephalalgia. 2008;28:1003-1011.
30. Merck Sharp & Dohme Corp. Merck Announces First-Quarter 2009 Financial Results [Company Press Release, April 21, 2009]. Merck Web site. [WWW document] URL: http://www.merck.com/newsroom/news-release-archive/financial/ 2009-0421.html. (accessed 1 March 2011).